Feinstein Institute for Medical Research
Latest From Feinstein Institute for Medical Research
Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.
Electroceuticals could replace the use of pharmaceuticals in many chronic diseases, offering effective treatments without, perhaps, side effects. Medtechs pioneering these next-gen neuromodulation devices are sparking investor interest.
In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.
GlaxoSmithKline will fund nonprofit labs across several biomedical and engineering disciplines and offer a $1 million cash prize to probe the role of neural activity in disease. The goal is to build new devices that treat a range of diseases “in their own electrical language.”
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.